Australia to begin human trials for COVID-19 vaccine made by China
Category: #headlines  By Saipriya Iyer  Date: 2020-04-29
  • share
  • Twitter
  • Facebook
  • LinkedIn
Australia to begin human trials for COVID-19 vaccine made by China

Linear Clinical Research, a research and clinical facility in Perth, Australia, has confirmed a human trial of a coronavirus vaccine that has been developed by China. Sources familiar with the matter said that research and clinical facility has already initiated the recruitment of healthy adults to participate in the trial within the coming two months.

S-Trimer vaccine, which is primarily developed by a biotechnology company called Clover Biopharmaceuticals, located in China, is believed to be one of the first COVID-19 vaccines to be under development. Linear had also made an announcement regarding the vaccine trial on the website and also called on the people who are interested in being registered with the company.

The company issued the statement that if people were feeling unhealthy and were located in Perth, WA, they could register their interest to be able to participate in the forthcoming COVID-19 vaccine study of the company.

According to a reliable source, the protein-based vaccine S-Trimer, is aimed at helping the body in producing anti-bodies to fight the virus.

Jayden Rogers, Linear’s chief executive commented that the trial was among the most vital trials across the globe and involves some extremely renowned vaccine firms. The S-Trimer vaccine had shown promising potential on the trial and has been placed at the forefront of the world’s battle with coronavirus pandemic.

The Chinese authorities had approved the human testing for two other COVID-19 vaccines recently in the month of April that were developed by the Wuhan Institute of Biological Products. This was done under the Sinovac Research and Development Co and China National Pharmaceutical Group (Sinopharm).

Apparently, Sinopharm has been able to produce more than 50,000 doses for the clinical trials. Once the production gets normalized, the output is capable of reaching about 3 million doses per batch and an annual output would be at 100 million doses.

 

Source Credit- https://www.aa.com.tr/en/asia-pacific/australia-set-for-chinese-covid-19-vaccine-human-trial-/1821328

 

  • share
  • Twitter
  • Facebook
  • LinkedIn

About Author

Saipriya Iyer

Saipriya Iyer    

Saipriya Iyer currently works as a content developer for GroundAlerts. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had previous experience of 3 years under her belt, she has dabbled with website ...

Read More >>

More News By Saipriya Iyer

IP Telephonic Market Segmentation, Analysis by Recent Trends, Development by Regions to 2026
IP Telephonic Market Segmentation, Analysis by Recent Trends, Development by Regions to 2026
By Saipriya Iyer

IP Telephonic market aims to decode lucrative investment opportunities in the business sphere and educate readers about the bottlenecks created by Covid-19 pandemic. The IP Telephonic market report incorporates all key aspects such as the predominan...

Latest Study explores the Anomaly Detection Market Witness Highest Growth in near future
Latest Study explores the Anomaly Detection Market Witness Highest Growth in near future
By Saipriya Iyer

Market Study Report, LLC, adds a thorough analysis of the ' Anomaly Detection market', offering a comprehensive report emphasizing every vital aspect of the business vertical. The study has collectively presented refined data characterized by market ...

Land Management Software Market Research Key Players, Industry Overview, Supply Chain and Analysis to 2021 – 2026
Land Management Software Market Research Key Players, Industry Overview, Supply Chain and Analysis to 2021 – 2026
By Saipriya Iyer

The ' Land Management Software Market' research report added by Market Study Report, LLC, delivers a comprehensive analysis on the newest market drivers. The report also offers extracts regarding statistics, market valuation and revenue estim...